Talphera, Inc. - Q3 2026 Financial Results Conference Call - TALPHERA INC

Explicit Guidance:

• Regulatory Timing: No explicit financial guidance provided; however, a target for regulatory closure (enrollment completion) of the NEFRO CRRT study is set for December 31, 2026.
• Data Availability: Topline data expected 4–6 weeks after enrollment closure.
• Capital Sufficiency: Current cash balance ($14.2M as of Sept 30, 2026) combined with two conditional financing tranches (~$16M total) is deemed sufficient to fund operations through at least the potential NIAID PMA approval in 2027.
• Financing Tranches: Two tranches (~$16M) expected to close around the time of top-line data release and study completion announcement.
• Filing Status: Plan to file a Form S3 Shelf Registration Statement to replace the existing S-3 expiring November 30, 2026.

Business-Segment Outlook:

• NIAID (Nefamistat) Regulatory Path: Proactively seeking FDA agreement to conclude enrollment early (at current levels >75%) rather than the original 70-patient target if necessary to meet the Dec 31, 2026 deadline.
• Commercial Potential: Updated peak annual US sales estimate for NIAID in CRRT increased to > $200 million, driven by physician feedback and unmet market needs.
• Market Growth Catalysts: Cited a recent NEJM study favoring CRRT over intermittent hemodialysis (stopped early due to higher mortality with intermittent dialysis) as a potential driver for overall CRRT market expansion.
• Guideline Alignment: KDIGO draft guidelines now elevate nifamistat as an alternative anticoagulant when citrate cannot be used, supporting commercial adoption.
• Investor Event: An investor and analyst event is planned for the first quarter of 2027 to discuss the commercial opportunity in detail.

Market and Competitive Outlook:

• Competitive Landscape: Noted that three recent citrate-based CRRT studies (including one by Fresenius Medical approved in Oct 2026 and one by Baxter/Vantiv) faced severe enrollment challenges, with some terminating or submitting early data due to inability to hit targets.
• Market Penetration Anomaly: Highlighted a divergence between clinical trial enrollment difficulties and real-world market adoption; citrate holds 25–30% market share despite being difficult to enroll for in trials.
• Differentiation: NIAID positions itself to overcome limitations of existing anticoagulants, targeting a therapeutic window rather than fixed dosing.

Macro / Industry Outlook:

• Clinical Trial Environment: Management characterizes enrollment in CRRT trials as "unpredictable" and "erratic," with recent enrollment dropping 85–90% compared to the prior year due to factors outside protocol control (patient exclusion criteria, consent issues, site performance variability).
• Regulatory Precedent: Cites industry precedent where studies with similar patient populations successfully obtained approval despite early enrollment closures and reduced sample sizes (e.g., Fresenius, Baxter/Vantiv).
• Safety Data Sufficiency: Asserts that due to 40 years of global use and existing safety databases (2004–2024 publications), a safety signal is unlikely to be missed with a smaller cohort, reducing the need for the originally planned 166 patients.

Strategic Initiatives:

• FDA Sprint Meeting: Submitted a briefing document requesting a "sprint meeting" under the Breakthrough Devices Program to validate the early closure strategy; feedback expected by the end of 2026.
• Operational Adjustment: Shifted strategy from achieving a fixed 70-patient target to maintaining statistical power (>80%) while adhering to the Dec 31, 2026, enrollment closure deadline to control timing.
• Contingency Plan: If the FDA rejects early closure, the company will continue enrolling to the original 70-patient target, potentially delaying filing to the first quarter of 2027.

Risks and Headwinds to Outlook:

• Enrollment Uncertainty: The primary headwind is the unpredictable and slow pace of enrolling critically ill ICU patients; management noted a 2–3 month period of "unexpectedly slow" enrollment.
• Regulatory Rejection: Risk that the FDA may not agree to the early closure proposal, necessitating a longer enrollment period.
• Capital Dependency: Funding relies on the successful closure of two conditional financing tranches (~$16M) upon meeting specific conditions tied to study milestones.
• Data Interpretation: While primary endpoints are statistically powered, secondary endpoints depend on the unique therapeutic window approach, which carries execution risk despite historical data support.

Management Tone on the Future:

• Confidence Level: High confidence in the study's ability to hit primary endpoints even with fewer patients, citing >80% statistical power and objective lab-based endpoints.
• Optimism: Expresses enthusiasm regarding the $200M+ market opportunity and the potential for patient access by the end of 2027 if timelines are met.
• Proactive Stance: Describes the FDA request as a "proactive approach" to avoid unnecessary delays and maintain control over the timeline despite enrollment volatility.
• Caution: Avoids guaranteeing FDA approval, noting "contingency plans" if the agency requests additional data or rejects the early closure proposal.

Miscellaneous:

• Study Power: Current enrollment provides >80% power for the primary endpoint (originally planned 90%+ with 70 patients); secondary endpoints are supported by historical studies with similar sample sizes (N=55–60).
• Site Engagement: Management reports no "fatigue" among Principal Investigators or sites; enthusiasm remains high due to the potential for rapid access to the therapy via the Breakthrough Device designation.